Cericlamine

Add links
Source: Wikipedia, the free encyclopedia.
Cericlamine
Clinical data
Routes of
administration		Oral[1]
ATC code
  • None
Pharmacokinetic data
Elimination half-life8 hours[1]
Identifiers
  • 3-(3,4-Dichlorophenyl)-2-(dimethylamino)-2-methylpropan-1-ol
JSmol)
  • CC(CC1=CC(=C(C=C1)Cl)Cl)(CO)N(C)C
  • InChI=1S/C12H17Cl2NO/c1-12(8-16,15(2)3)7-9-4-5-10(13)11(14)6-9/h4-6,16H,7-8H2,1-3H3
  • Key:FWYRGHMKHZXXQX-UHFFFAOYSA-N

Cericlamine (

derivative of phentermine, and closely related to chlorphentermine, a highly selective serotonin releasing agent) that was investigated as an antidepressant for the treatment of depression, anxiety disorders, and anorexia nervosa by Jouveinal but did not complete development and was never marketed.[1][2][3][4] It reached phase III clinical trials in 1996 before development was discontinued in 1999.[5]

According to Czech scientists, cericlamine is claimed to be part of a highly advanced “fifth generation” of antidepressants as was venlafaxine.[6]

The daily dosage was reported to be 300mg.[1]

See also

References

  1. ^
    S2CID 57983762
    .
  2. S2CID 25463729
    .
  3. ISBN 978-0-8247-8282-5
    .
  4. ISBN 978-1-4615-1857-0
    .
  5. ^ "Cericlamine". AdisInsight. Springer Nature Switzerland AG. Retrieved 13 January 2016.
  6. PMID 8174184
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cericlamine&oldid=1194222303"